OncoMatch/Clinical Trials/NCT05913089
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
Is NCT05913089 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including TQB2450 and TQB2450 for non small cell lung cancer.
Treatment: TQB2450 · TQB2450 — This is a clinical study on the efficacy and safety of TQB2450 injection combined with chemotherapy or anlotinib hydrochloride capsule in the perioperative treatment of resectable non-small cell lung cancer. The part I study was planned to enroll 58 subjects, 1:1 randomized into two cohorts. The treatment regimen was as follows: Cohort 1: 3-4 cycles of TQB2450 combined with chemotherapy, surgery should be performed 4-6 weeks after the last administration, and TQB2450 therapy should be continued for 1 year after surgery. Cohort 2: 4 cycles of TQB2450 combined with 3 cycles of anlotinib hydrochloride capsule. Surgery was performed 4-6 weeks after the last dose and continued for 1 year starting 4 weeks after surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage II, IIIA, IIIB (T3N2M0 ONLY)
patients with stage II-IIIB (T3N2M0 only) Non-Small Cell Lung Carcinoma (NSCLC) and determined to be eligible for curable R0 excision
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic antitumor therapy
Has not received systemic antitumor therapy, including radiotherapy, chemotherapy and immunotherapy
Cannot have received: hematopoietic stem cell transplant
Exception: within 60 days prior to initial medication
having received a hematopoietic stem cell transplant within 60 days prior to initial medication
Cannot have received: Chinese patent drugs with anti-tumor indications
Exception: within 2 weeks prior to initiation of administration
Received Chinese patent drugs with anti-tumor indications specified in the National Medical Product Administration approved drug package inserts within 2 weeks prior to initiation of administration
Cannot have received: major surgery
Exception: within 4 weeks prior to initiation of medication
Had major surgery within 4 weeks prior to initiation of medication
Lab requirements
Blood counts
Major organs are functioning well.
Kidney function
Major organs are functioning well.
Liver function
Major organs are functioning well.
Cardiac function
Major organs are functioning well.
Major organs are functioning well.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05913089 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA or IIIB (T3N2M0 ONLY) is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify